GE HealthCare Technologies (GEHC) Operating Cash Flow: History & Chart

GE HealthCare Technologies Inc.(GEHC)

Medical - Devices · Chicago, IL

$66.63+0.25 (+0.38%)

Delayed quote: Sep 25, 2026, 4:00 PM EDT

About GE HealthCare Technologies Inc.

GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.

Chicago, IL

54,000 employees

www.gehealthcare.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Peter J. Arduini

View full financials

Operating Cash Flow

Basis: latest reported fiscal quarter. Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly operating cash flow is ($517.00M). Operating cash flow is the cash generated by core business operations before capital expenditures.

Free Cash Flow|Capital Expenditure|Net Income|Cash Flow Statement|All Metrics

Operating Cash Flow

GEHC Operating Cash Flow

$-517.00M

Reported quarterly operating cash flow; no daily interpolation. Q2 FY2026 (2026-06-30): $-517.00M.

-199.42% over 10Y

GEHC Quarterly Operating Cash Flow Growth (YoY)

Operating Cash Flow growth vs the same fiscal quarter in the prior fiscal year, last 13 comparable quarters.

GEHC P/OCF Ratio

Full P/OCF Ratio page

P/OCF Ratio

GEHC P/OCF Ratio Chart

21.24

FMP quote market capitalization / four-quarter operating cash flow Quote observation: 2026-09-26T00:15:46.996Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.

Quarterly Operating Cash Flow History

Period	Operating Cash Flow	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	($517.00M)	N/A	N/A
Q1 FY2026Period end 2026-03-31	$290.00M	(72.41%)	+16.00%
Q4 FY2025Period end 2025-12-31	$1.05B	+77.23%	+15.12%
Q3 FY2025Period end 2025-09-30	$593.00M	+530.85%	(19.65%)
Q2 FY2025Period end 2025-06-30	$94.00M	(62.40%)	N/A
Q1 FY2025Period end 2025-03-31	$250.00M	(72.62%)	(40.33%)
Q4 FY2024Period end 2024-12-31	$913.00M	+23.71%	(13.05%)
Q3 FY2024Period end 2024-09-30	$738.00M	N/A	+13.54%
Q2 FY2024Period end 2024-06-30	($119.00M)	N/A	(77.61%)
Q1 FY2024Period end 2024-03-31	$419.00M	(60.10%)	(10.47%)
Q4 FY2023Period end 2023-12-31	$1.05B	+61.54%	+0.77%
Q3 FY2023Period end 2023-09-30	$650.00M	N/A	+4.50%
Q2 FY2023Period end 2023-06-30	($67.00M)	N/A	N/A
Q1 FY2023Period end 2023-03-31	$468.00M	(55.09%)	+0.00%
Q4 FY2022Period end 2022-12-31	$1.04B	+67.52%	N/A
Q3 FY2022Period end 2022-09-30	$622.00M	N/A	+7.61%
Q2 FY2022Period end 2022-06-30	($19.00M)	N/A	N/A
Q1 FY2022Period end 2022-03-31	$468.00M	N/A	(10.00%)
Q4 FY2021Period end 2021-12-31	($11.00M)	N/A	N/A
Q3 FY2021Period end 2021-09-30	$578.00M	+11.15%	N/A
Q2 FY2021Period end 2021-06-30	$520.00M	+0.00%	N/A
Q1 FY2021Period end 2021-03-31	$520.00M	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.